{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:49:29Z","timestamp":1775710169750,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s13318-024-00903-6","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T17:01:52Z","timestamp":1719248512000},"page":"583-594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Inhibitory Effect of Two Carbonic Anhydrases Inhibitors on the Activity of Major Cytochrome P450 Enzymes"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5238-2712","authenticated-orcid":false,"given":"Fawzy A.","family":"Elbarbry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamer M.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Abdelrahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-0323","authenticated-orcid":false,"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6996-4017","authenticated-orcid":false,"given":"Wagdy M.","family":"Eldehna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"903_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2023.129411","volume":"93","author":"CT Supuran","year":"2023","unstructured":"Supuran CT. A simple yet multifaceted 90 years old, evergreen enzyme: carbonic anhydrase, its inhibition and activation. Bioorgan Med Chem Lett. 2023;93: 129411.","journal-title":"Bioorgan Med Chem Lett"},{"key":"903_CR2","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1021\/cr200176r","volume":"112","author":"V Alterio","year":"2012","unstructured":"Alterio V, Di Fiore A, D\u2019Ambrosio K, Supuran CT, De Simone G. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? Chem Rev. 2012;112:4421.","journal-title":"Chem Rev"},{"key":"903_CR3","doi-asserted-by":"publisher","first-page":"6879","DOI":"10.2147\/OTT.S177605","volume":"11","author":"K Okuno","year":"2018","unstructured":"Okuno K, Matsubara T, Nakamura T, Iino T, Kakimoto T, Asanuma K, et al. Carbonic anhydrase IX enhances tumor cell proliferation and tumor progression in osteosarcoma. Onco Targets Ther. 2018;11:6879\u201386.","journal-title":"Onco Targets Ther"},{"key":"903_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/metabo10100412","volume":"10","author":"A Angeli","year":"2020","unstructured":"Angeli A, Carta F, Nocentini A, Winum J-Y, Zalubovskis R, Akdemir A, et al. Carbonic anhydrase inhibitors targeting metabolism and tumor microenvironment. Metabolites. 2020;10:412.","journal-title":"Metabolites"},{"key":"903_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18632\/oncotarget.422","volume":"3","author":"PC McDonald","year":"2012","unstructured":"McDonald PC, Winum J-Y, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget. 2012;3:84\u201397.","journal-title":"Oncotarget"},{"key":"903_CR6","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1002\/med.21713","volume":"40","author":"CB Mishra","year":"2020","unstructured":"Mishra CB, Tiwari M, Supuran CT. Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: where are we today? Med Res Rev. 2020;40:2485\u2013565.","journal-title":"Med Res Rev"},{"key":"903_CR7","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.4155\/fmc.14.68","volume":"6","author":"F Carta","year":"2014","unstructured":"Carta F, Supuran CT, Scozzafava A. Sulfonamides and their isosters as carbonic anhydrase inhibitors. Future Med Chem. 2014;6:1149\u201365.","journal-title":"Future Med Chem"},{"key":"903_CR8","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.3390\/ijms17071150","volume":"17","author":"CL Lomelino","year":"2016","unstructured":"Lomelino CL, Supuran CT, McKenna R. Non-classical inhibition of carbonic anhydrase. Int J Mol Sci. 2016;17:1150.","journal-title":"Int J Mol Sci"},{"key":"903_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104163","volume":"103","author":"T Al-Warhi","year":"2020","unstructured":"Al-Warhi T, Sabt A, Elkaeed EB, Eldehna WM. Recent advancements of coumarin-based anticancer agents: an up-to-date review. Bioorgan Chem. 2020;103: 104163.","journal-title":"Bioorgan Chem"},{"key":"903_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2022.105888","volume":"126","author":"HS Ibrahim","year":"2022","unstructured":"Ibrahim HS, Abdelrahman MA, Nocentini A, Bua S, Abdel-Aziz HA, Supuran CT, et al. Insights into the effect of elaborating coumarin-based aryl enaminones with sulfonamide or carboxylic acid functionality on carbonic anhydrase inhibitory potency and selectivity. Bioorgan Chem. 2022;126: 105888.","journal-title":"Bioorgan Chem"},{"key":"903_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115538","volume":"258","author":"WM Eldehna","year":"2023","unstructured":"Eldehna WM, Mohammed EE, Al-Ansary GH, Berrino E, Elbadawi MM, Ibrahim TM, et al. Design and synthesis of 6-arylpyridine-tethered sulfonamides as novel selective inhibitors of carbonic anhydrase IX with promising antitumor features toward the human colorectal cancer. Eur J Med Chem. 2023;258: 115538.","journal-title":"Eur J Med Chem"},{"key":"903_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s13318-019-00560-0","volume":"44","author":"F Elbarbry","year":"2019","unstructured":"Elbarbry F, Ung A, Rao D, Abdelkawy K. Effect of dietary doses of quercetin on hepatic drug metabolizing enzymes in spontaneously hypertensive rats. Eur J Drug Metab Pharmacokinet. 2019;44:761\u201370.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"903_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2174\/1389450118666170125144557","volume":"19","author":"P Manikandan","year":"2018","unstructured":"Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 2018;19:38\u201354.","journal-title":"Curr Drug Targets"},{"key":"903_CR14","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1124\/dmd.107.017590","volume":"35","author":"J Alcorn","year":"2007","unstructured":"Alcorn J, Elbarbry FA, Allouh MZ, McNamara PJ. Evaluation of the assumptions of an ontogeny model of rat hepatic cytochrome P450 activity. Drug Metab Dispos Biol Fate Chem. 2007;35:2225\u201331.","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"903_CR15","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s13318-016-0352-3","volume":"42","author":"KS Abdlekawy","year":"2017","unstructured":"Abdlekawy KS, Donia AM, Elbarbry F. Effects of grapefruit and pomegranate juices on the pharmacokinetic properties of dapoxetine and midazolam in healthy subjects. Eur J Drug Metab Pharmacokinet. 2017;42:397\u2013405.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"903_CR16","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/ptr.5397","volume":"29","author":"A Amin","year":"2015","unstructured":"Amin A, CanGongora M, Elbarbry F. Dietary doses of sulforaphane affect hepatic drug metabolizing enzymes in spontaneously hypertensive rats. Phytother Res PTR. 2015;29:1412\u201320.","journal-title":"Phytother Res PTR"},{"key":"903_CR17","unstructured":"Research C for DE and. Clinical drug interaction studies\u2014cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry [Internet]. US Food Drug Adm. 2020 [cited 2021 Feb 17]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions. Accessed 1 Dec 2023."},{"key":"903_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1080\/14756366.2018.1547286","volume":"34","author":"WM Eldehna","year":"2019","unstructured":"Eldehna WM, Hassan GS, Al-Rashood ST, Al-Warhi T, Altyar AE, Alkahtani HM, et al. Synthesis and in vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents. J Enzyme Inhib Med Chem. 2019;34:322\u201332.","journal-title":"J Enzyme Inhib Med Chem"},{"key":"903_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4789","volume":"34","author":"V Nguyen","year":"2020","unstructured":"Nguyen V, Espiritu M, Elbarbry F. Development and validation of a sensitive and specific LC-MS\/MS cocktail assay for CYP450 enzymes: Application to study the effect of catechin on rat hepatic CYP activity. Biomed Chromatogr BMC. 2020;34: e4789.","journal-title":"Biomed Chromatogr BMC"},{"key":"903_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/jbt.20156","volume":"21","author":"FA Elbarbry","year":"2007","unstructured":"Elbarbry FA, McNamara PJ, Alcorn J. Ontogeny of hepatic CYP1A2 and CYP2E1 expression in rat. J Biochem Mol Toxicol. 2007;21:41\u201350.","journal-title":"J Biochem Mol Toxicol"},{"key":"903_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1124\/jpet.105.093229","volume":"316","author":"RS Obach","year":"2006","unstructured":"Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther. 2006;316:336\u201348.","journal-title":"J Pharmacol Exp Ther"},{"key":"903_CR22","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1021\/ci100436p","volume":"51","author":"M McGann","year":"2011","unstructured":"McGann M. FRED pose prediction and virtual screening accuracy. J Chem Inf Model. 2011;51:578\u201396.","journal-title":"J Chem Inf Model"},{"key":"903_CR23","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s10822-012-9584-8","volume":"26","author":"M McGann","year":"2012","unstructured":"McGann M. FRED and HYBRID docking performance on standardized datasets. J Comput Aided Mol Des. 2012;26:897\u2013906.","journal-title":"J Comput Aided Mol Des"},{"key":"903_CR24","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1021\/ci100031x","volume":"50","author":"PCD Hawkins","year":"2010","unstructured":"Hawkins PCD, Skillman AG, Warren GL, Ellingson BA, Stahl MT. Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J Chem Inf Model. 2010;50:572\u201384.","journal-title":"J Chem Inf Model"},{"key":"903_CR25","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine. Guidance for industry: bioanalytical method validation. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm070107.pdf. Accessed 1 Mar 2024."},{"key":"903_CR26","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1021\/jm060519r","volume":"49","author":"JK Yano","year":"2006","unstructured":"Yano JK, Denton TT, Cerny MA, Zhang X, Johnson EF, Cashman JR. Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006;49:6987\u20137001.","journal-title":"J Med Chem"},{"key":"903_CR27","first-page":"296","volume":"268","author":"NL Benowitz","year":"1994","unstructured":"Benowitz NL, Jacob P, Fong I, Gupta S. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther. 1994;268:296\u2013303.","journal-title":"J Pharmacol Exp Ther"},{"key":"903_CR28","first-page":"418","volume":"18","author":"DE Williams","year":"1990","unstructured":"Williams DE, Shigenaga MK, Castagnoli N. The role of cytochromes P-450 and flavin-containing monooxygenase in the metabolism of (S)-nicotine by rabbit lung. Drug Metab Dispos. 1990;18:418\u201328.","journal-title":"Drug Metab Dispos"},{"key":"903_CR29","doi-asserted-by":"publisher","first-page":"850","DOI":"10.2174\/138920021610151210164501","volume":"16","author":"X He","year":"2015","unstructured":"He X, Feng S. Role of metabolic enzymes P450 (CYP) on activating procarcinogen and their polymorphisms on the risk of cancers. Curr Drug Metab. 2015;16:850\u201363.","journal-title":"Curr Drug Metab"},{"key":"903_CR30","first-page":"7581","volume":"63","author":"H Takeuchi","year":"2003","unstructured":"Takeuchi H, Saoo K, Yokohira M, Ikeda M, Maeta H, Miyazaki M, et al. Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A\/J mice. Cancer Res. 2003;63:7581\u20133.","journal-title":"Cancer Res"},{"key":"903_CR31","doi-asserted-by":"crossref","unstructured":"Daly AK. Chapter three - polymorphic variants of cytochrome P450: relevance to cancer and other diseases. In: Hardwick JP, editor. Adv Pharmacol [Internet]. Academic Press; 2015 [cited 2024 Mar 7]. p. 85\u2013111. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1054358915000277. Accessed 1 Dec 2023.","DOI":"10.1016\/bs.apha.2015.03.001"},{"key":"903_CR32","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/ntr\/ntab175","volume":"24","author":"SK Jones","year":"2021","unstructured":"Jones SK, Wolf BJ, Froeliger B, Wallace K, Carpenter MJ, Alberg AJ. Nicotine metabolism predicted by CYP2A6 genotypes in relation to smoking cessation: a systematic review. Nicotine Tob Res. 2021;24:633\u201342.","journal-title":"Nicotine Tob Res"},{"key":"903_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/jpm7040018","volume":"7","author":"J-A Tanner","year":"2017","unstructured":"Tanner J-A, Tyndale RF. Variation in CYP2A6 activity and personalized medicine. J Pers Med. 2017;7:18.","journal-title":"J Pers Med."},{"key":"903_CR34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/03602532.2019.1632889","volume":"51","author":"J Chen","year":"2019","unstructured":"Chen J, Jiang S, Wang J, Renukuntla J, Sirimulla S, Chen J. A comprehensive review of cytochrome P450 2E1 for xenobiotic metabolism. Drug Metab Rev. 2019;51:178\u201395.","journal-title":"Drug Metab Rev"},{"key":"903_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-94-007-5881-0_8","volume":"67","author":"C Heit","year":"2013","unstructured":"Heit C, Dong H, Chen Y, Thompson DC, Deitrich RA, Vasiliou V. The role of CYP2E1 in alcohol metabolism and sensitivity in the central nervous system. Subcell Biochem. 2013;67:235\u201347.","journal-title":"Subcell Biochem"},{"key":"903_CR36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1006\/taap.1997.8134","volume":"144","author":"Y Li","year":"1997","unstructured":"Li Y, Wang EJ, Chen L, Stein AP, Reuhl KR, Yang CS. Effects of phenethyl isothiocyanate on acetaminophen metabolism and hepatotoxicity in mice. Toxicol Appl Pharmacol. 1997;144:306\u201314.","journal-title":"Toxicol Appl Pharmacol"},{"key":"903_CR37","doi-asserted-by":"publisher","first-page":"486","DOI":"10.2174\/1389200216666150812123554","volume":"16","author":"PSS Rao","year":"2015","unstructured":"Rao PSS, Midde NM, Miller DD, Chauhan S, Kumar A, Kumar S. Diallyl sulfide: potential use in novel therapeutic interventions in alcohol, drugs, and disease mediated cellular toxicity by targeting cytochrome P450 2E1. Curr Drug Metab. 2015;16:486\u2013503.","journal-title":"Curr Drug Metab"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00903-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-024-00903-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00903-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T18:11:48Z","timestamp":1725127908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-024-00903-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["903"],"URL":"https:\/\/doi.org\/10.1007\/s13318-024-00903-6","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"assertion":[{"value":"26 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no financial or nonfinancial interests that are directly or indirectly related to the work submitted for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The data that support the findings of this study can be made available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors have substantially contributed to this study as follows: F.E., C.T.S., and W.M.E. conceptualized the study; F.E. and M.A.A. conducted the methodology; T.M.I. performed software analysis; F.E., T.M.I., and M.A.A. performed validation; T.M.I. performed formal analysis; F.E. and W.M.E. carried out the investigation; F.E. obtained the resources; T.M.I. and M.A.A. performed data curation; F.E., T.M.I., and W.M.E. performed writing\u2014original draft preparation; F.E., T.M.I., and C.T.S. performed writing\u2014review and editing; F.E. and W.M.E. supervised the study; F.E., and C.T.S. performed project administration. All authors have read and agreed to the published version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}